Brands Set Sights On Lame-Duck Session After Opioid Bill Excludes Part D Deal

By John Wilkerson Ariel Cohen / September 26, 2018 at 10:44 AM

The final version of opioid legislation excludes brand-drug industry-backed Part D changes, and now brand lobbyists have set their sights on the lame-duck session for getting Congress to lower the industry’s share of seniors’ drug costs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.